Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand

Blood

Volumn 93, Issue 9, 1999, Pages 2999-3007

  Hirano, Akio ^b   Longo, Dan L ^b   Taub, Dennis D ^b   Ferris, Douglas K ^b   Young, Lawrence S ^b   Eliopoulos, Arisitides G ^b   Agathanggelou, Angelo ^b   Cullen, Nicky ^b   Macartney, James ^b   Fanslow, William C ^b   Murphy, William J ^a  

^a SAIC FREDERICK INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON;

ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033135236     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.9.2999     Document Type: Article

References (22)

1. Banchereau J, Bazan F, Blanchard D, Driere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 12:881, 1994
2. Foy TM, Fiona H, Noelle D, Noelle RJ: The expansive role of CD40 and its ligand, gp39, in immunity. Immunology 6:259, 1994
3. Van Kooten C, Banchereau J: Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 9:330, 1997
4. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS: CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 92:4342, 1995
5. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR, Clarke EA, Smith CA, Grabstein KH, Cosman D, Spriggs MK: Molecular and biological characterization of a murine ligand for CD40. Nature 357:80, 1992
6. Stamenkovic I, Clark EA, Seed B: A B lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 8:1403, 1989
7. Thomas WD, Smith MJ, Si Z, Hersey P: Expression of the co-stimulatory molecule CD40 on melanoma cells. Int J Cancer 68:795, 1996
8. Ashwell JD, Longo DL, Bridges SH: T-cell tumor elimination as a result of T-cell receptor-mediated activation. Science 237:61, 1987
9. Eray M, Tuomikoski T, Wu H, Nordstrom T, Andersson LC, Knuutila S, Kaartinen M: Cross-linking of surface IgG induces apoptosis in a bcl-2 expressing human follicular lymphoma line of mature B cell phenotype. Int Immunol 6:1817, 1994
10. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ: Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83:2787, 1994
11. Murphy WJ, Funakoshi S, Beckwith M, Rushing SE, Conley SK, Armitage RJ, Fanslow WC, Rager HC, Taub DD, Ruscetti FW, Longo DL: Antibodies to CD40 prevent Epstein-Barr virus-mediated human B cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood 86:1946, 1995
12. American Cancer Society: Cancer Facts and Figures. New York, NY, American Cancer Society, 1996
13. Armitage RJ, Tough TW, Macduff BM, Fanslow WC, Spriggs MK, Ramsdell F, Alderson MR: CD40 ligand is a T cell growth factor. Eur J Immunol 23:2326, 1993
14. Engel LW, Young NA: Human breast carcinoma cells in continuous culture: A review. Cancer Res 38:4327, 1978
15. Carmichel J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47:936, 1987
16. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS: CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 92:4342, 1996
17. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E, Young LS: CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator. Oncogene 13:2243, 1996
18. Funakoshi S, Longo DL, Murphy WJ: Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J Immunother 19:93, 1996
19. Vestal RE, Wingett DG, Knight LK, Stillinger RA, Cantor GH, Nielson CP, Fanslow WC, Ghalie R: Expression of CD40 in breast, colon, lung, and ovarian tumors. Proc Am Assoc Cancer Res 38:A1550, 1997 (abstr)
20. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK: CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178:669, 1993
21. Funakoshi S, Taub DD, Anver MR, Raziuddin A, Asai O, Reddy V, Rager H, Fanslow WC, Longo DL, Murphy WJ: Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. J Clin Invest 99:484, 1997
22. Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, Holden W, Brenner M: CD40 Ligand induces an antileukemia response in vivo. Blood 90:1927, 1997